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Abstract
There is a continuing need for new health technologies to address the disease burdens of developing countries. In
the last decade Product Development Partnerships (PDP) have emerged that are making important contributions
to the development of these technologies. PDPs are a form of public private partnerships that focus on health
technology development. PDPs reflect the current phase in the history of health technology development: the Era
of Partnerships, in which the public and private sectors have found productive ways to collaborate. Successful
innovation depends on addressing six determinants of innovation. We examine four case studies of PDPs and
show how they have addressed the six determinants to achieve success.
Introduction
Developing countries facem a n yc h a l l e n g e st ot h e i r
social and economic development. With limited
resources, they need to provide education to their chil-
dren, ensure an adequate supply of food, stimulate the
development of industry, build up an efficient transpor-
tation system, and provide health care to the population,
among many others. To be successful in addressing
these challenges, developing countries must be able to
harness new technologies that are rapidly becoming
available. In recent years, there have been rapid
advances in the development and availability of new
health technologies especially new vaccines and drugs
for diseases that exact a heavy burden on developing
countries. These include new vaccines against diarrhea,
respiratory infections, and cervical cancer, and drugs
such as the highly active antiretroviral therapies
(HAART) for AIDS, and drugs for malaria. The avail-
ability of these new technologies holds great promise for
addressing important diseases in developing countries,
but also presents great challenges in financing and deli-
vering these technologies to people in need.
Despite these recent advances in health technology
there remain many diseases for which there are inade-
quate or no technologies that can reduce their burden
on health. There are pressing needs for vaccines against
AIDS, malaria, and tuberculosis, and against neglected
tropical diseases (NTDs) such as hookworm, schistoso-
miasis, and dengue. There is also a need for new and
improved drugs against most of these diseases [1].
These twin challenges of financing and delivering
existing technologies and developing new and improved
technologies have led to important initiatives by devel-
oping countries and by the global health community.
The Global Fund to Fight AIDS, Tuberculosis and
Malaria has been established to mobilize donor funds to
procure and supply needed drugs for developing coun-
tries [2]. The GAVI Alliance similarly has been estab-
lished to procure and supply needed vaccines for
developing countries [3]. Both have been able to raise
billions of dollars on an annual basis for these important
undertakings. Not only have they seen the need to
finance the procurement of these technologies but they
have also increasingly appreciated the challenges of deli-
vering the technologies in developing countries. They
have been allocating increasing funds to support health
systems development.
With respect to the development of new and
improved technologies, a number of additional new
initiatives have been launched. These initiatives are
referred to as product development partnerships (PDPs)
that address a wide range of diseases and work on accel-
erating the development of drugs, vaccines, diagnostics
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the PDPs is the Bill & Melinda Gates Foundation. Sup-
port has also been provided by the World Bank, other
foundations, and bilateral donors. The PDPs have, in
common, a strategy of promoting collaboration between
public and private sector institutions in developed and
developing countries. The PDPs are nonprofit entities
operating with philanthropic funds and form collabora-
tive partnerships with private sector health technology
corporations to design and implement product develop-
ment programs for specific health technologies. For
example, the PATH Malaria Vaccine Initiative has been
working closely with GlaxoSmithKline Biologicals in the
development of a malaria vaccine which is now in Phase
3 trials in African countries. The Global Alliance for TB
Drug Development (TB Alliance) has been working with
a number of companies in the development of new
drugs against tuberculosis. The Pediatric Dengue Vac-
cine Initiative of the International Vaccine Institute has
been working with a number of companies to promote
the development of five candidate vaccines against
dengue.
T h el a u n c ho ft h e s ev a r i o u sP D P si sak e yp a r to ft h e
current era of health technology innovation which we
refer to as the Era of Partnerships [4]. The Era of Part-
nerships is the fourth in a series of Eras in modern
health technology innovation reaching back to the
1850s. Each of these Eras has been characterized by dif-
ferent levels of engagement and investment by the pub-
lic and private sectors.
In the Era of the Public Sector (1850 to 1915), health
technology innovation was dominated by public sector
institutions primarily in Europe and epitomized by the
work of Louis Pasteur and the Pasteur Institute to
develop and disseminate vaccines around the world. The
Era of the Private Sector (1915 to 1970) was launched
by the realization of European - predominantly German
- chemical companies that there was a highly profitable
market for drugs. This led to a rapidly increasing level
of investment in the pharmaceutical industry including
research, development, manufacture, and marketing.
This Era led to the development and global distribution
of a large number of important technologies that revolu-
tionized health care. However, with the end of the Sec-
ond World War, and led by the United States, a
number of developed country governments and founda-
tions became concerned that the health technology
revolution had largely bypassed the poor in developing
countries. Not only were the new technologies not
reaching the poor in developing countries, but technolo-
gies that were needed by people in developing countries
were not being developed. This realization led to the
Era of Public Sector Reawakening (1970 to 2000) and
involved support for efforts to develop new
contraceptives at the Population Council in New York
City and the Human Research Programme (HRP) at
WHO in Geneva, and a variety of technologies at the
Tropical Disease Research Program (WHO), and PATH,
a 501(c)3 non-profit in Seattle, Washington. Not only
did these programs succeed in developing several new
technologies that were introduced into developing coun-
tries but they provided an essential and invaluable
means for designing and testing strategies by which the
public sector could stimulate the development of health
technologies for use in developing countries. One of the
foremost lessons learned from this experience was that
close collaboration between the public and private sec-
tor was essential for success. From the perspective of
the second decade of the 21st century, this lesson may
seem obvious. But in the early 1970s, there was a huge
gulf between the public and private sectors about health
technology innovation. The public sector characterized
the private sector as largely unsympathetic to the needs
of the poor and especially the poor in developing coun-
tries. The private sector characterized the public sector
as being largely incapable of developing new health
technologies and with little understanding of how to
develop, manufacture, and market health technologies in
a sustainable manner.
But, based on the new body of knowledge from the
operation of the various public sector product develop-
ment groups, and largely funded by the Bill & Melinda
Gates Foundation, the Era of Partnerships was
launched around the year 2000. This Era is character-
ized by an accommodation between the public and pri-
vate sectors in which each sees that the other has
something to contribute to their individual and collec-
tive goals. It has involved the establishment of a large
number of PDPs including for vaccines against malaria,
HIV, tuberculosis (TB), hookworm, meningitis, cholera,
dengue, and pneumococcal disease, and for drugs
against malaria, TB, HIV infection, visceral leishmania-
sis, and technologies such as diagnostics. Each of these
PDPs forms strong partnerships with private compa-
nies that are governed by formal agreements dealing
with issues including intellectual property, regulatory
pathways, markets, manufacture, and price. The objec-
tive of these agreements is to lay out rules of the colla-
boration that meet the differing and complementary
goals of the partners. The PDP wants a safe, effective
and affordable product available to the poor in devel-
oping countries. The company wants a safe, effective
and affordable product that provides a robust return
on investment. During the last decade, an increasingly
formal system of exchange of information and manage-
ment know how has evolved among the PDPs that has
allowed them to benefit from knowledge of what
works and what doesn’tw o r k .
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sons that have been learned about how PDPs and pri-
vate sector pharmaceutical firms can effectively
collaborate to promote innovation in global health. We
use the case study methodology.
Methods
This work was conducted by examination of publicly
available documents and by interviews with key indivi-
duals at each of the organizations which are the subject
of this study. The case studies examined herein were
selected on several criteria. The programs of all PDPs
were reviewed through websites, annual reports and
newsletters, and examples of successful projects were
selected. A subset of those projects was selected where
there was the availability of the most detailed documen-
tation about the project. The final criterion was the
availability of staff at the PDPs willing to discuss the
projects in detail and provide important information.
Results
We propose that there are six broad areas of collabora-
tion - determinants of innovation - between public and
private sector organizations to promote innovation in
health technologies [5].
1. The design and execution of research and devel-
opment programs from preclinical studies to
licensure.
2. Analysis and planning for the marketing and dis-
tribution of new technologies in individual develop-
ing countries
3. Analysis and planning for the procurement and
supply of new health technologies by the global
health community
4. Planning and implementation of manufacturing
capabilities
5. Establishment and implementation of regulatory
systems to ensure safe and effective products
6. Establishment and implementation of intellectual
property rights (IPR) management systems
These six determinants of innovation are comprehen-
sive in that they span all activities that are necessary
and sufficient for the development, and introduction of
health technologies in developing countries. We exam-
ine several case studies that illustrate the need to
address each of the determinants of innovation albeit in
different proportions depending on the product.
Medicines for Malaria Venture and Coartem
® Dispersible
The Medicines for Malaria Venture (MMV) is based in
Geneva Switzerland and was founded in November 1999
with funding from the Rockefeller Foundation, the
World Bank, and the governments of Switzerland, the
United Kingdom and the Netherlands. Its expenditures
on research and development grew from about $2.3 mil-
lion in 2000 to an average of about $45 million from
2006 through 2009 [6]. MMV operates according to a
standard R&D process with the following components:
compound screening and hit-to-lead identification, lead
optimization, preclinical development and candidate
selection, clinical phase 1, clinical phase 2, clinical phase
3, and registration and launch. In 2006, MMV com-
mitted also to prioritize Access & Delivery work in
ensuring the broad uptake and health impact of pro-
ducts that emerge from its drug development pipeline -
this area of work focuses around enhancing the accep-
tance (internationally and nationally), uptake (particu-
larly in rural access-deprived areas), and measurement
of impact of MMV products in “real-life” settings.
MMV has collaborated with pharmaceutical compa-
nies in the screening and hit-to-lead identification
component of the R&D process. For example, they
have undertaken a screening initiative to harness pri-
vate sector research capabilities to examine large
libraries of small molecule compounds for effectiveness
against the malaria parasite. Collaboration takes place
in all other stages of the process. In addition to pro-
viding funding, MMV also provides substantial know
how, technical and supervisory inputs by its staff and
through an Expert Advisory Committee and also seeks
in-kind contributions in the form of staff, laboratory
space, equipment and operates with a zero overhead
policy.
In collaboration with Novartis, MMV has developed
and launched a combination treatment for malaria,
Coartem
® Dispersible. This product is a sweet-tasting,
dispersible pediatric dose formulation of a malaria drug
combination treatment used widely for adults. It is
highly effective and well accepted by children. The intel-
lectual property including know-how belongs to Novar-
tis for both the combined use of the active ingredients,
artemether and lumefantrine, and for the dispersible for-
mulation. The agreement between MMV and Novartis
includes a commitment by Novartis to distribute the
product in malaria-endemic countries. If Novartis fails
to do so, MMV gets a sub-licensable license to manu-
facture and sell in those countries. Further Novartis
agreed to make the product available at cost to the pub-
lic sector in malaria-endemic countries [7]. To bring
this product to developing countries, MMV sponsored
clinical bridging studies that assessed the safety and effi-
cacy of the new formulation in children [8] and allowed
the registration of this new product. In December 2009,
it was approved by Swissmedic, then went on to obtain
WHO prequalification, and was placed on the WHO
essential medicines list.
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national regulatory agencies. MMV worked with Novar-
tis to establish adequate production, to formulate exten-
sive plans for marketing and distributing the product,
and helped develop the regulatory pathway. MMV has
also engaged country policymakers to encourage the
revision of national treatment guidelines in favor of
improved solutions for treating pediatric malaria. Lastly,
MMV collaborates with Novartis in training health
workers and supporting national initiatives to make
Coartem Dispersible more widely available in rural areas
through the promotion of community-healthcare-worker
programming.
As of June 2010, over 35 million treatments have been
supplied. In sum, MMV addressed all six determinants
of innovation leading to a successful outcome. It sup-
ported product development, collaborated on produc-
tion scale up, helped arrange regulatory approvals,
entered into facilitating IP management arrangements,
and helped developed international and national distri-
bution systems.
PATH and the Japanese encephalitis project
PATH was founded in the mid-1970s and has grown to
be one of the world’s largest non-profit technology orga-
nizations concerned with health in developing countries.
One of its projects was to promote the introduction of
Japanese encephalitis vaccine into Bangladesh and India
[9]. Japanese encephalitis is the leading cause of viral
encephalitis in Asia and is the leading neurological
infection in that region. Throughout Asia there are
50,000 cases reported annually and it is believed that
this number represents a severe underreporting. There
are 10,000 to 15,000 deaths annually with a 5 percent to
35 percent case fatality rate. Of considerable importance
with respect to Japanese encephalitis is the post-infec-
tion disability rate which ranges from 30 percent to 75
percent of cases and is primarily neurological. A vaccine
against Japanese encephalitis has been available for
many years but its use has been limited. This vaccine is
produced using fetal mouse brains. Use of the vaccine
has been limited because of inadequate supply due to
the difficult production process, cost of production, a
difficult administration schedule, and, probably most
important, concern about side effects resulting from
mouse brain material remaining in the vaccine. A less
expensive and less reactogenic vaccine, referred to as
SA-14-14-2, was developed in China and could be admi-
nistered in a two-dose regimen over 2.5 months to
achieve high levels of protection [10]. The PATH pro-
ject had the goal of introducing this vaccine into Bangla-
desh and India.
The project in India had to overcome many barriers.
First, there was not a full appreciation by policymakers
in India of the importance of Japanese encephalitis as
a disease. Therefore a surveillance program was under-
taken that documented the significant incidence of
Japanese encephalitis and its burden on the health sys-
tem. Second, while medical professionals in India
appreciated that the mouse brain vaccine was asso-
ciated with certain side effects, they were not willing
to accept the introduction of the Chinese vaccine
b e c a u s et h e yw e r eu n s u r ea b o u tt h er i g o ro ft h eC h i -
nese national regulatory authority. To address this bar-
rier, PATH facilitated a rigorous review of all available
data of clinical testing and evaluation of the Chinese
vaccine. The WHO Global Advisory Committee on
Vaccine Safety also carried out a review of the data for
the SA-14-14-2 vaccine and acknowledged the excel-
lent safety and efficacy profile while calling for some
additional clinical studies of the vaccine. Another
important event was the licensure by the Korean FDA
of the Chinese vaccine (the KFDA has WHO
approval). These reviews and licensure led to an accep-
tance by Indian authorities (National Technical Advi-
sory Group on Immunization and the national
regulatory agency) of the Chinese vaccine. Another
issue with respect to supply is the policy of India to
rely on domestic manufacturers for supply of its vac-
cines. Indian authorities wished to have the know-how
for production of the vaccine transferred to India, but
the Chinese authorities did not agree to this request.
Eventually the Indian decision-makers accepted the
s i t u a t i o no nt h ec o n d i t i o nt h a tal o c a lI n d i a ng o v e r n -
ment company (Hindustan Latex Limited) be the agent
for the Chinese manufacturer. Once Indian authorities
accepted the idea of introducing the vaccine, there
were a number of activities that needed to be com-
pleted including the prepara t i o no fa ni n t r o d u c t i o n
plan, operational guidelines, training materials, and
vaccine procurement. It was also necessary to set up a
monitoring and evaluation plan including monitoring
of adverse events following immunization. Finally clini-
cal studies had to be designed and implemented to
measure immunogenicity, safety and viremia [11].
In sum, PATH addressed all six determinants of
innovation. The key issues in the introduction of an
improved Japanese encephalitis vaccine into India
involved establishing a domestic market, i.e. a vaccina-
tion program, resolving numerous regulatory issues,
and establishing an international supply mechanism of
the vaccine from China to India. Manufacturing issues
were addressed through interactions with the Chinese
producer. Finally, IP issues were important to the
extent that they involved the unwillingness of the Chi-
nese manufacturer to transfer the production technol-
ogy to India, but this matter was successfully
addressed.
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Vaccine Initiative (CHOVI)
The International Vaccine Institute (IVI) was founded in
Seoul, Korea in 1997 as an autonomous international
organization under the Vienna Convention. The treaty
establishing the IVI has 40 country signatories plus
WHO. It is the only international organization com-
mitted to the development of new vaccines for people in
developing countries. It has managed several PDPs
including ones for cholera, shigellosis, and salmonella
(DOMI - Diseases of the Most Impoverished), cholera
(CHOVI - Cholera Vaccine Initiative), typhoid (VIVA -
Vi Typhoid Vaccine Program), and for dengue (PDVI -
Pediatric Dengue Vaccine Initiative - see below). The
cholera program which grew out of the DOMI program
has successfully addressed the need for highly qualified
vaccine production facilities in developing countries.
The cholera case study [12] is an important illustra-
tion of the links among the determinants of innovation.
Establishing manufacturing facilities has to take into
account both market (domestic and international) and
regulatory considerations. As argued by Lall [13], in
terms of innovation, a company’s entry into interna-
tional markets is fundamentally different from entry into
domestic markets. Entering the international market in
pharmaceuticals requires that the product meets certain
regulatory standards which are often much more rigor-
ous than those to be found in most developing coun-
tries. Countries importing vaccines produced in
developing countries will often require that the vaccines
be approved by one or more regulatory authorities of
developed countries. Alternatively they may require that
the vaccine obtain WHO pre-qualification. To provide
pre-qualification, WHO sends teams of highly skilled
individuals to assess the vaccine including the produc-
tion facility and the national regulatory authority. The
vaccine is pre-qualified only if both the production facil-
ity and the national regulatory authority meet certain
requirements [14]. Additionally, cholera is a disease
affected some of the poorest countries and these coun-
tries will have to rely on donors to obtain the vaccine.
Often donors use UNICEF procurement services and
UNICEF also required WHO prequalification.
Vietnam had established the production of a cholera
vaccine with technology transfer from Sweden. There
were certain problems in the Vietnamese facility with
compliance with the WHO guidelines for the produc-
tion of killed oral cholera vaccines and with the quality
of the vaccine including residual cholera toxin. The IVI,
mostly at its facilities in Seoul, worked with the Vietna-
mese facility and addressed these compliance issues and
were able to improve the vaccine in several ways. The
new vaccine formulation and new quality control assays
were made available to the Vietnamese manufacturer
and are now being used by that manufacturer. However
it was now necessary to establish production in a coun-
try that had a WHO prequalified national regulatory
authority. The IVI staff facilitated the transfer of the
technology to Shantha Biotechnics in India which had
been successful in obtaining WHO prequalification for
other vaccines. Clinical trials of this new cholera vaccine
were conducted in both Vietnam and India by the IVI
with Vietnamese (NIHE) and Indian (NICED) collabora-
tors, and the vaccine was found to be both safe and
effective [15]. The vaccine has been licensed in both
countries and is being introduced into immunization
programs. Subsequent to this work, a controlling inter-
est in Shantha was acquired by sanofi pasteur, a mem-
ber of the sanofi aventis group, from bioMerieux.
The next step will be to export the vaccine to other
developing countries. As noted above, this will require
the producers to obtain some form of regulatory review
satisfactory to the importing countries which will in
most cases include WHO prequalification. This will be
an important further step in the development of innova-
tive capabilities of the producers and the relevant gov-
ernment agencies.
This case study illustrates how a PDP, focusing on the
needs of the poor in developing countries, can be suc-
cessful in improving the manufacturer of a needed vac-
cine and transferring the technology to multiple
developing countries. Because cholera is a disease that
occurs among only the poor in developing countries, it
is certain that only the public sector would be willing to
allocate the required resources to achieve this success.
However the ultimate success of the program required
the participation of a private sector manufacturing com-
pany in India.
It is important to note also that this cholera case
study provides a very robust example of a PDP generat-
i n ga n de m p l o y i n ge x t e n s i v eb a c k g r o u n dd a t ao nt h e
incidence, disease burden, and vaccine demand and will-
ingness to pay, and then applying those data to support
vaccine demonstration projects and vaccine cost effec-
tiveness analyses [16-23]. This evidence provided a basis
for a presentation to WHO SAGE which recommended
use of the vaccine in late 2009 [24]. Finally, IVI has pre-
pared a detailed Vaccine Investment Case to support
the procurement and distribution of the vaccine in
endemic countries. The comprehensive approach used
by IVI illustrates how success can be ensured by a PDP
addressing research, domestic and international markets,
regulatory, and production issues in a highly integrated
way.
An interesting aspect of this case study is that there
were no patents that either facilitated or constrained the
process. However the IVI and its collaborators devel-
oped important intellectual property rights in the form
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agreements. Thus, IP was important to the success of
this project even in the absence of patents. This is the
general case with respect to vaccines where know how
is often more important than patents.
In sum, IVI addressed all determinants of innovations
- issues of product development, scale up of manufac-
ture, regulatory approvals, IP management, and develop-
ment of national and international distribution systems.
Work continues on the international distribution
challenges.
The International Vaccine Institute and the Pediatric
Dengue Vaccine Initiative (PDVI)
Dengue is the world’s most important vector-borne viral
disease threatening over 3.6 billion people worldwide
and resulting in more than 500,000 cases per annum.
While mortality from the disease is low (about 23,000
deaths per year most among children), morbidity asso-
ciated with dengue levies heavy burdens on developing
countries for their health systems and for individual
families who must pay the costs of treatment for this
disease.
The PDVI was established in 2002 and has received
funding from the Rockefeller Foundation and the Bill &
Melinda Gates Foundation. Its programs have been
designed specifically to address each of the six compo-
nents of innovation [25]. It has invested in facilitating
research and development on a number of new vaccines
being sponsored by a variety of companies, both public
and private. It has worked on developing a global
demand and appreciation of the importance of dengue
vaccine through advocacy activities. It has worked with
individual countries to plan for the introduction of the
new vaccines to their domestic markets. For both
domestic and global markets, it carried out an extensive
evaluation of the potential uptake of dengue vaccines in
an initial five-year period following licensure [26]. The
PDVI undertook an extensive assessment of the intellec-
tual property rights situation with respect to dengue
vaccines and concluded that there were no significant
barriers to the development of the current portfolio of
vaccines in advanced testing [unpublished data]. The
PDVI, in close collaboration with the World Health
Organization, has worked extensively on establishing a
regulatory pathway for dengue vaccines [27]. A detailed
discussion of the PDVI programs has been published
[25]. Substantial progress has been achieved in dengue
vaccine development with licensure of a first vaccine
possible in 2014. In the next several years, attention will
be directed towards developing country-specific intro-
duction plans, establishing provisional vaccine strategies,
clarifying the epidemiology and burden of disease of
dengue, and ensuring adequate manufacturing facilities
worldwide to supply the expected large demand for den-
gue vaccines. [In January 2011, the PDVI was renamed
the Dengue Vaccine Initiative consisting of a consortium
of four organizations: IVI, International Vaccine Access
Center of Johns Hopkins Blumberg School of Public
Health, the Initiative for Vaccine Research of WHO,
and the Sabin Vaccine Institute.]
In sum, the PDVI has addressed the six determinants
of innovation. It supported two companies to complete
preclinical research including production scale up. It
addressed issues of IP management, regulatory
approvals, and development of national and interna-
tional distribution systems. Work on the last two issues
is a high priority for the continuing activities of DVI.
Discussion
These case studies illustrate how PDPs address each of
the six determinants of innovation (see Table 1). The
relative extent to which they address each determinant
varies according to a number of variables including the
product, the target group of affected individuals, the
countries into which the product will be introduced,
and the willingness of industry to invest in product. Pro-
gress achieved varies on the stage of the product’s devel-
opment at the time the PDP initiates its work. Also the
relative priority accorded to each determinant of innova-
tion will differ depending on the stage of product devel-
opment. For example, manufacture is much more
important if a product is approaching licensure for
distribution.
Over the last decade, PDPs have become an increasingly
important means to accelerate the development of health
technologies for neglected diseases. By 2007, they obtained
(omitting funding by the U.S. NIH which focuses on basic
research) 42.0% of external global research and develop-
ment funding for neglected diseases [28]. While in the
early years there was uncertainty about whether PDPs
could be successful [29,30], it is now generally accepted
that they can be and have been effective [28].
However, they are a relatively new form of organiza-
tion for health innovation. Before the mid-1990s, there
were only a few non-profit organizations attempting to
undertake product development in health. One of these
was PATH which had been launched in the mid-1970s.
The PATH experience has been summarized by Elias
[31]. He describes a value chain of five stages. These
five stages encompass the six determinants of innovation
as we indicate by inserting the determinant numbers
that are related to each stage. discovery and research (1,
6), development of discoveries into usable products (1,
4, 6), regulatory processes to ensure product safety and
licensure (5), introduction of new technologies into
health systems (2), and scale-up and effective use of pro-
ducts by populations (2, 3, 4).
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PDPs, and they have also used other models such as
biotechnology companies and product development
arms of pharmaceutical companies. However, as noted
by Elias, it is exactly in the areas of understanding of
health systems in developing countries and introducing
products into those health systems (what we refer to as
analysis and planning for the marketing and distribution
of new technologies in individual developing countries)
where private industry often does not have in-depth
experience. Thus, the PDPs have been engaged in creat-
ing, largely ab initio, a comprehensive system and meth-
odology for product innovation while launching and
implementing programs, i.e. they have been engaged in
“learning by doing.”
Of particular interest is the evolution of the under-
standing of the role of IP in health technology devel-
opment and access. This is well illustrated by the work
of the UK and WHO on IP. In the 1990s and early
2000s, it was often asserted that patents and other
forms of IP were major factors limiting access by the
poor to new health technologies. A Commission
formed by the UK examined this issue in depth. The
argument was well summarized in the Commission’s
report [32]:
On the one side, the developed world side, there
exists a powerful lobby of those who believe that all
IPRs are good for business, benefit the public at large
and act as catalysts for technical progress. They
believe and argue that, if IPRs are good, more IPRs
must be better. On the other side, the developing
world side, there exists a vociferous lobby of those
who believe that IPRs are likely to cripple the devel-
opment of local industry and technology, will harm
the local population and benefit none but the devel-
oped world. They believe and argue that, if IPRs are
bad, the fewer the better.
The Commission’s report is comprehensive and com-
plex. The report notes that research and development of
new products and their eventual availability to the poor
are affected by a wide range of factors.
The heart of the problem is the lack of market
demand sufficient to induce the private sector to
Table 1 PDP work on determinants of innovation
Case
Study
R&D National Markets International Markets Manufacture Regulatory Systems IP management
MMV and
Coartem
Dispersible
Sponsored
clinical trials
Supports training of
local health workers
and expansion of use
of product by new
community health
worker programs.
Engages national
policymakers to
encourage policy shift
in favor of improved
child treatment and
survival.
Ensure alignment of
product with Global
Fund, UNICEF and PMI
requirements for
international
procurement.
Collaborated with
Novartis in international
launch and
communication
activities around
product introduction.
Worked with
Novartis to plan
for production
volume
Helped back regulatory
pathway for eventual
approval in 24 countries.
Facilitate country specific
regulatory review in key
countries in sub-Saharan
Africa.
Obtained access
commitments from
Novartis which have
ensured accessible/
affordable pricing of
product for public
sector uptake.
PATH and
JE vaccine
Sponsored
surveillance
research.
Helped set
up
monitoring
and
evaluation
plan.
Helped establish state-
level distribution
programs
Arranged international
supply of vaccine from
China
Obtained
agreement for
continued
manufacture in
China
Facilitated review by
Indian authorities to
obtain approval
Respected China
producers rights and
obtained agreement
for supply at low price
IVI and
cholera
vaccine
Undertook
clinical trials
to evaluate
safety and
efficacy
Establishing an
investment case for
cholera vaccine
In progress Developed new
production and
quality control
methodologies
and transferred
to Vietnam and
India
Obtained licensure in
India and Vietnam
Developed know how
which was protected
to ensure control of
product
IVI and
dengue
vaccine
Helped two
biotech
move
product from
lab to Phase
1 study
Undertook study of
potential markets in
most endemic
countries
Initiated work with
international agencies
to raise awareness of
dengue
Worked with
developing
country
manufacture to
establish
production
Worked with WHO and
national regulatory
authorities to develop
pathway
Undertook detailed
freedom to operate
study showing no
serious constraints
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Page 7 of 9commit resources to R&D. Therefore, we believe that
presence or absence of IP protection in developing
countries is of at best secondary importance in gener-
ating incentives for research directed to diseases pre-
valent in developing countries.
Subsequent to the work of the UK Commission,
WHO formed a Commission on Intellectual Property
Rights, Innovation and Public Health. It similarly con-
cluded [33]:
In successive phases of the innovation cycle - from
fundamental research to the discovery, development
and delivery of new products - the multiplicity of
financial and other incentive mechanisms, and the
scientific and institutional complexities of biomedical
innovation have had to be considered. At each phase
intellectual property rights may play a greater or les-
ser role in facilitating the innovation cycle. Other
incentive and financing mechanisms to stimulate
research and development of new products are
equally necessary, along with complementary mea-
sures to promote access.
T h u s ,a sa r g u e di nt h i sp a p e r ,I Pi si m p o r t a n ta n di t
can affect access - both positively and negatively - but it
is only one of six factors that affect innovation. And it is
rarely the most important factor.
There are differences between PDPs that address
drugs and those that address vaccines. Those that
address drugs especially where they are working on
reformulations of existing products or devising new pro-
duction methods, as in the cases of MMV and TB Alli-
ance, have sufficient resources to “own” the products, i.
e. they pay for the development, testing and regulatory
licensure. The costs for this kind of work are in the tens
of millions of dollars. Under these circumstances they
can have great control of plans for marketing, distribu-
tion and pricing. Those that address vaccines (the
Meningitis Vaccine Program at PATH is an exception)
rarely have the required funds to own the product and
are much more reliant on the resources of private com-
panies. The total cost of developing a new vaccine may
well exceed $1 billion. Under these circumstances, the
PDPs have less influence on development, marketing
and distribution and other determinants. Nevertheless,
both kinds of PDPs must address the six determinants
of innovation.
Perhaps the most important development of the last
decade is that PDPs have shown to be a critical and
necessary component in ensuring access by the poor in
developing countries to needed health technologies
(Wells 2011). Recent moves by additional donors such
as the Department for International Development of the
United Kingdom, Ministry of Foreign Affairs of the
Netherlands, and the Ministry of Foreign Affairs of Ger-
many to allocate more money to PDPs indicate that this
new organizational framework should be sustainable for
years to come. A critical factor in achieving sustainabil-
ity, as laid out in this paper and elsewhere [34], will be
for the PDPs to address each of the six determinants of
innovation. Success in doing so will be key to success in
their work, which will be the strongest argument for
sustained support.
This paper seeks to contribute to the development of
a comprehensive system and methodology by bringing
to bear the insights of innovations studies with the
actual experience of PDPs.
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